A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Gemcitabine (Primary) ; Glofitamab (Primary) ; Oxaliplatin (Primary) ; Obinutuzumab; Tocilizumab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 08 Oct 2024 New trial record